Tuesday, April 18, 2023
Neuspera® Medical announced that it has received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturised system.
The system is comprised of a micro-implant that delivers neurostimulation therapy through a wireless platform including a wearable transmitter and iPad-based clinician programmer. The Neuspera ultra-miniaturised system has the potential to revolutionise the way physicians treat patients battling chronic pain while restoring patients’ health and quality of life.
The Neuspera system delivers peripheral nerve stimulation (PNS) through a wireless, less invasive, and more versatile platform than commercially available technology. It is the first PNS device that offers an ultra-miniaturised option, allowing for a better patient experience and greater procedural flexibility.
It is 75x smaller than the smallest commercial implantable pulse generator and provides physicians the opportunity for deeper anatomical targets compared to current technologies available today.
